Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Telmisartan Does Not Significantly Reduce Risk of Recurrent Stroke, Cardiovascular Events - (DGNews)
    Percutaneous Coronary Intervention Not Inferior to Bypass Grafting in Diabetic Patients With Multivessel Disease: Presented at ESC - (DGDispatch)
    Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis - (BMJ)
    TopAbstracts in Diabetes 09/02/2008 - (DGNews)
    Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events - (N Engl J Med)

    News archive

     Recent webcasts/CME - Diabetes
      Cardiometabolic Risk and Risk Management
      An Evolving Approach to the Treatment of Type 2 Diabetes
      Obesity, Type 2 Diabetes, and Cardiovascular Disease
      Global Perspectives on Diabetic Retinopathy: More Than Meets the Eye
      Type 1 Diabetes - New Insights into Pathophysiology, Treatment, and the Search for a Cure

      Webcasts/CME archive

       Recent cases - Diabetes
        Diabetic Fetopathy Associated with Bilateral Adrenal Hyperplasia and Ambiguous Genitalia: A Case Report
        Somatostatinoma: A Rare Cause of Diabetic Ketosis
        New Onset Diabetes Complicated by Haemolysis and Rhabdomyolysis: A Case Report and Review of the Literature
        Diabetic Control and Atypical Antipsychotics: A Case Report
        Treatment with Pioglitazone Induced Significant, Reversible Mitral Regurgitation

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Niacin May Be Effective Therapy For Broad Range Of Diabetes-Associated Dyslipidaemias

        A DGReview of :"Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes"
        Diabetes, Obesity & Metabolism

        07/25/2002
        By Andrew A. Skolnick


        Niacin is an effective therapy for treating a broad range of atherogenic dyslipidemias in many patients with diabetes.

        Researchers at the Diabetes Research Center, in Tustin, California and the University of California, Irvine in the United States conducted a study of 42 diabetic patients with abnormal blood lipid profiles, who were treated with niacin.

        Before and after treatment, J. Pan and colleagues measured the patients' serum triglycerides, small, dense low density lipoprotein cholesterol (LDLc) particle mass, LDL particle size, total high density lipoprotein C (HDLc) and high density lipoprotein 2 (HDL2) percentage, and lipoprotein(a) [LP(a)].

        After niacin treatment, the patients' LDL peak particle diameter increased from 252 ± 7 Å to 263 ± 7, the researchers reported. Their small, dense LDLc particle mass decreased from 27 ± 11 mg/dL to 15 ± 4 mg/dL. Total HDLc increased from 39 ± 7 mg/dL to 51 ± 11 mg/dL. Their HDL2, as the percentage of total HDLc mass, increased from 29 ± 8 percent to 45 ± 10 percent, and their Lp(a) decreased from 43 ± 17 mg/dL to 25 ± 10 mg/dL.

        With the use of increased oral therapy and insulin doses in more than 90 percent of patients, their mean haemoglobin A1c level improved from 7.6 ± 1.8 percent to 6.5 ± 1.0 percent.

        Twenty-one percent of the patients were unable to tolerate niacin because of reversible adverse effects. Another 14 percent were unable to adhere to the niacin dosing regimen of three times daily, the authors reported.

        Based on these findings, niacin is an effective therapy for a broad range of diabetic dyslipidaemias associated with both the atherogenic lipid profile and Lp(a). However, it must be used with modern and aggressive oral hypoglycaemic agents or insulin treatment, the researchers concluded.
        Diabetes Obes Metab 2002; 4: 255-261. "Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send